tiprankstipranks
Solventum Corporation (MX:SOLV)
:SOLV
Mexico Market
SOLV
Solventum Corporation
RESEARCH TOOLSreports

Solventum Corporation (SOLV) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

SOLV Analyst Ratings

Moderate Buy
10Ratings
Moderate Buy
7 Buy
3 Hold
0 Sell
Based on 10 analysts giving stock ratings to
Solventum
Corporation
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

SOLV Stock 12 Month Forecast

Average Price Target

$1,688.44
▲(22.17% Upside)
Based on 10 Wall Street analysts offering 12 month price targets for Solventum Corporation in the last 3 months. The average price target is $1,688.44 with a high forecast of $1,936.99 and a low forecast of $1,439.88. The average price target represents a 22.17% change from the last price of $1,382.00.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1106":"$1,106","1937":"$1,937","1313.75":"$1,313.8","1521.5":"$1,521.5","1729.25":"$1,729.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1936.98789766,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$1.94K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1688.43635327,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$1.69K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1439.88480888,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$1.44K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1106,1313.75,1521.5,1729.25,1937],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1382,1424.691376743077,1467.382753486154,1510.0741302292308,1552.7655069723078,1595.4568837153847,1638.1482604584617,1680.8396372015386,1723.5310139446156,1766.2223906876925,1808.9137674307694,1851.6051441738462,1894.296520916923,{"y":1936.98789766,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1382,1405.5720271746154,1429.1440543492308,1452.7160815238462,1476.2881086984614,1499.8601358730768,1523.4321630476923,1547.0041902223077,1570.576217396923,1594.1482445715385,1617.7202717461537,1641.292298920769,1664.8643260953845,{"y":1688.43635327,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1382,1386.4526776061539,1390.9053552123078,1395.3580328184617,1399.8107104246153,1404.2633880307692,1408.716065636923,1413.168743243077,1417.6214208492308,1422.0740984553847,1426.5267760615384,1430.9794536676923,1435.4321312738462,{"y":1439.88480888,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1350.06,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1392.5,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1359,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1560,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1560,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1560,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1338,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1107.61,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1134.01,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1320,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1382,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1382,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1382,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$1,937Average Price Target$1,688Lowest Price Target$1,440
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
BTIG Analyst forecast on MX:SOLV
Ryan Zimmerman
BTIG
BTIG
$1,628.44
Buy
17.83%
Upside
Reiterated
09/14/26
Analysts Offer Insights on Healthcare Companies: Butterfly Network (NYSE: BFLY), Tonix Pharma (NASDAQ: TNXP) and Solventum Corporation (NYSE: SOLV)
UBS Analyst forecast on MX:SOLV
Patrick Wood
UBS
UBS
$1,731.29
Buy
25.27%
Upside
Assigned
08/20/26
UBS Releases a Buy Rating on Solventum Corporation (SOLV)
BMO Capital Analyst forecast on MX:SOLV
Vik Chopra
BMO Capital
BMO Capital
$1,439.88
Hold
4.19%
Upside
Reiterated
08/17/26
BMO Capital Keeps Their Hold Rating on Solventum Corporation (SOLV)
Bank of America Securities Analyst forecast on MX:SOLV
Travis Steed
Bank of America Securities
Bank of America Securities
$342.83→$1,628.44
Hold
17.83%
Upside
Reiterated
08/11/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Haleon PLC Sponsored ADR (NYSE: HLN), Arcus Biosciences (NYSE: RCUS) and Solventum Corporation (NYSE: SOLV)
Mizuho Securities Analyst forecast on MX:SOLV
Steven Valiquette
Mizuho Securities
Mizuho Securities
$1,714.15→$1,936.99
Buy
40.16%
Upside
Reiterated
08/06/26
Solventum price target raised to $113 from $100 at MizuhoSolventum price target raised to $113 from $100 at Mizuho
Stifel Nicolaus Analyst forecast on MX:SOLV
Rick Wise
Stifel Nicolaus
Stifel Nicolaus
$1,542.73→$1,714.15
Buy
24.03%
Upside
Reiterated
08/06/26
Analysts' Top Healthcare Picks: Enliven Therapeutics (ELVN), Solventum Corporation (SOLV)
Wedbush Analyst forecast on MX:SOLV
Michael Piccolo
Wedbush
Wedbush
$1,611.3→$1,731.29
Buy
25.27%
Upside
Reiterated
08/06/26
Wedbush Sticks to Their Buy Rating for Solventum Corporation (SOLV)
KeyBanc Analyst forecast on MX:SOLV
Brett Fishbin
KeyBanc
KeyBanc
$1,594.16→$1,748.43
Buy
26.51%
Upside
Reiterated
08/06/26
Analysts Offer Insights on Healthcare Companies: Xencor (NASDAQ: XNCR), Alpha Teknova (NASDAQ: TKNO) and Solventum Corporation (NYSE: SOLV)
Wells Fargo Analyst forecast on MX:SOLV
Nathan Treybeck
Wells Fargo
Wells Fargo
$1,199.9→$1,525.59
Hold
10.39%
Upside
Reiterated
08/06/26
Solventum Corporation (SOLV) Receives a Hold from Wells Fargo
Piper Sandler Analyst forecast on MX:SOLV
Jason Bednar
Piper Sandler
Piper Sandler
$1,577.02→$1,799.86
Buy
30.24%
Upside
Reiterated
08/06/26
Solventum Corporation (SOLV) Gets a Buy from Piper Sandler
Goldman Sachs Analyst forecast on MX:SOLV
David Roman
Goldman Sachs
Goldman Sachs
$1,131.34
Sell
-18.14%
Downside
Reiterated
05/05/26
Analysts Offer Insights on Healthcare Companies: Ocugen (NASDAQ: OCGN), Vertex Pharmaceuticals (NASDAQ: VRTX) and Solventum Corporation (NYSE: SOLV)
J.P. Morgan Analyst forecast on MX:SOLV
Mark Strouse
J.P. Morgan
J.P. Morgan
―
Buy
―
Initiated
04/06/26
Solventum Corporation (SOLV) Gets a Buy from J.P. Morgan
Rothschild & Co Redburn Analyst forecast on MX:SOLV
Unknown Analyst
Rothschild & Co Redburn
Not Ranked
Rothschild & Co Redburn
$1,028.49
Sell
-25.58%
Downside
Initiated
03/24/26
Solventum initiated with a Sell at Rothschild & Co RedburnSolventum initiated with a Sell at Rothschild & Co Redburn
Argus Research Analyst forecast on MX:SOLV
David Toung
Argus Research
Argus Research
―
Buy
―
Reiterated
12/12/25
Argus Research Remains a Buy on Solventum Corporation (SOLV)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
BTIG Analyst forecast on MX:SOLV
Ryan Zimmerman
BTIG
BTIG
$1,628.44
Buy
17.83%
Upside
Reiterated
09/14/26
Analysts Offer Insights on Healthcare Companies: Butterfly Network (NYSE: BFLY), Tonix Pharma (NASDAQ: TNXP) and Solventum Corporation (NYSE: SOLV)
UBS Analyst forecast on MX:SOLV
Patrick Wood
UBS
UBS
$1,731.29
Buy
25.27%
Upside
Assigned
08/20/26
UBS Releases a Buy Rating on Solventum Corporation (SOLV)
BMO Capital Analyst forecast on MX:SOLV
Vik Chopra
BMO Capital
BMO Capital
$1,439.88
Hold
4.19%
Upside
Reiterated
08/17/26
BMO Capital Keeps Their Hold Rating on Solventum Corporation (SOLV)
Bank of America Securities Analyst forecast on MX:SOLV
Travis Steed
Bank of America Securities
Bank of America Securities
$342.83→$1,628.44
Hold
17.83%
Upside
Reiterated
08/11/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Haleon PLC Sponsored ADR (NYSE: HLN), Arcus Biosciences (NYSE: RCUS) and Solventum Corporation (NYSE: SOLV)
Mizuho Securities Analyst forecast on MX:SOLV
Steven Valiquette
Mizuho Securities
Mizuho Securities
$1,714.15→$1,936.99
Buy
40.16%
Upside
Reiterated
08/06/26
Solventum price target raised to $113 from $100 at MizuhoSolventum price target raised to $113 from $100 at Mizuho
Stifel Nicolaus Analyst forecast on MX:SOLV
Rick Wise
Stifel Nicolaus
Stifel Nicolaus
$1,542.73→$1,714.15
Buy
24.03%
Upside
Reiterated
08/06/26
Analysts' Top Healthcare Picks: Enliven Therapeutics (ELVN), Solventum Corporation (SOLV)
Wedbush Analyst forecast on MX:SOLV
Michael Piccolo
Wedbush
Wedbush
$1,611.3→$1,731.29
Buy
25.27%
Upside
Reiterated
08/06/26
Wedbush Sticks to Their Buy Rating for Solventum Corporation (SOLV)
KeyBanc Analyst forecast on MX:SOLV
Brett Fishbin
KeyBanc
KeyBanc
$1,594.16→$1,748.43
Buy
26.51%
Upside
Reiterated
08/06/26
Analysts Offer Insights on Healthcare Companies: Xencor (NASDAQ: XNCR), Alpha Teknova (NASDAQ: TKNO) and Solventum Corporation (NYSE: SOLV)
Wells Fargo Analyst forecast on MX:SOLV
Nathan Treybeck
Wells Fargo
Wells Fargo
$1,199.9→$1,525.59
Hold
10.39%
Upside
Reiterated
08/06/26
Solventum Corporation (SOLV) Receives a Hold from Wells Fargo
Piper Sandler Analyst forecast on MX:SOLV
Jason Bednar
Piper Sandler
Piper Sandler
$1,577.02→$1,799.86
Buy
30.24%
Upside
Reiterated
08/06/26
Solventum Corporation (SOLV) Gets a Buy from Piper Sandler
Goldman Sachs Analyst forecast on MX:SOLV
David Roman
Goldman Sachs
Goldman Sachs
$1,131.34
Sell
-18.14%
Downside
Reiterated
05/05/26
Analysts Offer Insights on Healthcare Companies: Ocugen (NASDAQ: OCGN), Vertex Pharmaceuticals (NASDAQ: VRTX) and Solventum Corporation (NYSE: SOLV)
J.P. Morgan Analyst forecast on MX:SOLV
Mark Strouse
J.P. Morgan
J.P. Morgan
―
Buy
―
Initiated
04/06/26
Solventum Corporation (SOLV) Gets a Buy from J.P. Morgan
Rothschild & Co Redburn Analyst forecast on MX:SOLV
Unknown Analyst
Rothschild & Co Redburn
Not Ranked
Rothschild & Co Redburn
$1,028.49
Sell
-25.58%
Downside
Initiated
03/24/26
Solventum initiated with a Sell at Rothschild & Co RedburnSolventum initiated with a Sell at Rothschild & Co Redburn
Argus Research Analyst forecast on MX:SOLV
David Toung
Argus Research
Argus Research
―
Buy
―
Reiterated
12/12/25
Argus Research Remains a Buy on Solventum Corporation (SOLV)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
PTGXProtagonist Therapeutics
ESTAEstablishment Labs Holdings
HITIHigh Tide
JAZZJazz Pharmaceuticals
OMCLOmnicell
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Solventum Corporation

3 Months
Jason BednarPiper Sandler
Success Rate
8/10 ratings generated profit
80%
Average Return
+9.41%
Copying Jason Bednar's trades and holding each position for 3 Months would result in 80.00% of your transactions generating a profit, with an average return of +9.41% per trade.
1 Year
Brett FishbinKeyBanc
Success Rate
5/5 ratings generated profit
100%
Average Return
+16.48%
Copying Brett Fishbin's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +16.48% per trade.
2 Years
Jason BednarPiper Sandler
Success Rate
10/10 ratings generated profit
100%
Average Return
+19.28%
Copying Jason Bednar's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +19.28% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

SOLV Analyst Recommendation Trends

Rating
May 26
Jun 26
Jul 26
Aug 26
Sep 26
Strong Buy
1
1
0
0
0
Buy
12
12
10
13
12
Hold
7
5
5
5
5
Sell
2
1
1
0
0
Strong Sell
0
0
0
0
0
total
22
19
16
18
17
In the current month, SOLV has received 12 Buy Ratings, 5 Hold Ratings, and 0 Sell Ratings. SOLV average Analyst price target in the past 3 months is 1,688.44.
Each month's total comprises the sum of three months' worth of ratings.

SOLV Financial Forecast

SOLV Earnings Forecast

Next quarter’s earnings estimate for SOLV is $22.84 with a range of $21.57 to $24.29. The previous quarter’s EPS was $43.31. SOLV beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year SOLV has Performed in-line its overall industry.
Next quarter’s earnings estimate for SOLV is $22.84 with a range of $21.57 to $24.29. The previous quarter’s EPS was $43.31. SOLV beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year SOLV has Performed in-line its overall industry.

SOLV Sales Forecast

Next quarter’s sales forecast for SOLV is $32.84B with a range of $32.55B to $33.45B. The previous quarter’s sales results were $37.51B. SOLV beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year SOLV has Performed in-line its overall industry.
Next quarter’s sales forecast for SOLV is $32.84B with a range of $32.55B to $33.45B. The previous quarter’s sales results were $37.51B. SOLV beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year SOLV has Performed in-line its overall industry.

SOLV Stock Forecast FAQ

What is MX:SOLV’s average 12-month price target, according to analysts?
Based on analyst ratings, Solventum Corporation’s 12-month average price target is 1,688.44.
    What is MX:SOLV’s upside potential, based on the analysts’ average price target?
    Solventum Corporation has 22.17% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Solventum Corporation a Buy, Sell or Hold?
          Solventum Corporation has a consensus rating of Moderate Buy, which is based on 7 buy ratings, 3 hold ratings and 0 sell ratings.
            What is Solventum Corporation’s share price target?
            The average share price target for Solventum Corporation is 1,688.44. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is $1,936.99 ,and the lowest forecast is $1,439.88. The average share price target represents 22.17% Increase from the current price of $1,382.
              What do analysts say about Solventum Corporation?
              Solventum Corporation’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 10 Wall Streets Analysts.
                How can I buy shares of Solventum Corporation?
                To buy shares of MX:SOLV, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.